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Pluripotent stem cells (PSCs) transition between cell states in vitro and reflect 119 
developmental changes in the early embryo. PSCs can be stabilized in the naïve 120 
state by blocking extracellular differentiation stimuli, particularly FGF-MEK 121 
signaling. Here, we report that multiple features of the naïve state in human and 122 
mouse PSCs can be recapitulated without affecting FGF-MEK-signaling or global 123 
DNA methylation. Mechanistically, chemical inhibition of CDK8 and CDK19 124 
kinases removes their ability to repress the Mediator complex at enhancers. Thus 125 
CDK8/19 inhibition increases Mediator-driven recruitment of RNA Pol II to 126 
promoters and enhancers. This efficiently stabilizes the naïve transcriptional 127 
program and confers resistance to enhancer perturbation by BRD4 inhibition. 128 
Moreover, naïve pluripotency during embryonic development coincides with a 129 
reduction in CDK8/19. We conclude that global hyperactivation of enhancers 130 
drives naïve pluripotency, and this can be achieved in vitro by inhibiting CDK8/19 131 
kinase activity. These principles may apply to other contexts of cellular plasticity.132 





Each cell-type contains a unique repertoire of active enhancer complexes at 134 
specific DNA regions, which arise by high concentration of lineage-specific 135 
transcription factors and signaling pathways1–3. The Mediator complex is 136 
enriched at enhancers, where it integrates multiple upstream signals and recruits 137 
RNA polymerase II (RNA Pol II) to nearby and distant promoters4–6. A large 138 
fraction of Mediator and other transcriptional machinery clusters within a small 139 
number of unusually long multipartite enhancers, known as super-enhancers 140 
(SEs)2,3,7. SEs drive high expression of the master transcription factors which 141 
maintain cell identity, yet SEs also possess vulnerability to perturbation via sharp 142 
transitions in their phase separation2,3,7. Given Mediator´s central role in 143 
enhancer-driven transcription, modulation of its activity may influence cellular 144 
identity and plasticity7,8. Indeed, global enhancer activation was identified across 145 
multiple human cancers9. The kinase CDK8 and its similar but poorly studied 146 
paralog CDK19 represent the only enzymatic activity of the 30-subunit Mediator 147 
complex4–6. This CDK8/19 sub-module can regulate RNA Pol II recruitment via its 148 
kinase activity, although it may also sterically hinder the association between 149 
Mediator and RNA Pol II5,6,10–13. Accordingly, chemical inhibition of CDK8/19 150 
results in global hyperactivation of enhancer function within cancer cells14. 151 
Additional layers of complexity include that CDK8 can phosphorylate multiple 152 
Mediator subunits, the RNA Pol II C-terminal regulatory domain, chromatin 153 
regulators and transcription factors4–6,11–17. 154 
 155 
Pluripotent stem cells (PSC) provide a prototypical model of cellular 156 
plasticity, whose transcriptional program can be stabilized, extinguished or re-157 
captured18–23. While human PSCs offer great therapeutic promise, successful 158 
clinical applications remain few, as human pluripotency is less characterized and 159 
less stable in vitro, than in mice21,22,24. Chemical inhibition of MEK and GSK3 160 
kinases with a two-inhibitor cocktail known as “2i” shields mouse PSCs cells from 161 
extra-cellular differentiation in a state known as naïve pluripotency25. Mouse 162 
PSCs cultured in 2i (referred to as “2i-naïve” cells) phenocopy the stable and 163 
homogenous state of undifferentiated naïve pluripotency that exists transiently in 164 
the E4.5 pre-implantation embryo epiblast18,19,25. In contrast, culture of PSCs 165 




without 2i shifts cell identity towards post-implantation epiblast ~E6.5, also known 166 
as primed pluripotency18,19,23. Enhancer destabilization by chemical blockade of 167 
BRD4, a key component of enhancers and SEs, triggers loss of Mediator-driven 168 
gene expression in many cell types, and induces differentiation in primed 169 
PSCs26–28. Remarkably, 2i-naïve PSCs are highly resistant to enhancer 170 
destabilization28, indicating an association between naïve pluripotency and 171 
enhancer stability/resilience. MEK-inhibition has been implicated upstream of 172 
potent and rapid reconfiguration of the transcriptome, proteome, and DNA 173 
methylome, within embryonic or 2i-naïve pluripotency18–20,23. However, the 174 
molecular mediators of 2i that are responsible for enhancer stabilization remain 175 
unclear.  176 
 177 
Here, we assess the impact of Mediator-CDK8/19-kinase inhibition on 178 
PSC identity, in order to elucidate the transcriptional basis of their plasticity. In 179 
summary, stimulating Mediator through its kinase module represses 180 
differentiation, favors self-renewal, and upregulates pre-implantation naïve 181 
epiblast gene expression in mouse and in human. 182 
 183 
RESULTS 184 
Inhibition of Mediator kinase stabilizes mouse naïve pluripotency  185 
GFP knock-in reporters at key stem cell marker genes such as Nanog represent 186 
well-established and precise indicators of the naïve (GFPhigh) and primed states 187 
(GFPlow)18,22,29. For example, in 2i-naïve state, Nanog promoter activity is 188 
enhanced, yielding a characteristically homogenous Nanog-GFPhigh cell 189 
expression pattern and uniform dome-shaped colonies (Fig.1A-C, and Extended 190 
Data Fig.1A). In contrast, the Nanog promoter is metastable in primed state 191 
PSCs, reversibly oscillating between high and low activity, presenting a 192 
heterogeneous Nanog-GFP expression pattern and flattened diffuse colonies, 193 
indicative of a general underlying switch in transcriptional program18,20,23,29,30. The 194 
BRD4 inhibitor JQ1 destabilizes enhancers and resulted in colony flattening and 195 
GFPlow status (Fig.1A), as reported26–28. In this experimental setting, we tested 196 
the effect of manipulating the transcriptional cyclin-dependent kinases (CDK7, 197 
CDK8/19 and CDK9) with a panel of small molecule inhibitors. Several potent 198 




and structurally-unrelated CDK8/19 inhibitors had a positive effect, inducing the 199 
formation of homogenous dome-shaped colonies, and upregulating both the 200 
Nanog-GFP reporter and endogenous Nanog expression, similar to PSC in the 201 
2i-naïve state (Fig.1A-E; Extended Data Fig.1A; Supplementary Table 1), 202 
while inhibition of CDK7 or CDK9 did not. Potency and selectivity of CDK8/19-203 
inhibitors, commercially available or developed in-house, were assessed by 204 
multiple methods: (i) selectivity was suggested by a KinomeScan panel of 456 205 
kinases; (ii) Lanthascreen assays demonstrated inhibitory activity at nanomolar 206 
concentrations against pure recombinant CDK8/CCNC and CDK19/CCNC; (iii) 207 
luciferase reporter cell assays (TOP-FLASH); and (iv) potent inhibition of STAT1-208 
Ser727 phosphorylation in human PSCs, a well-documented CDK8 target 209 
site11,14,16,31 (Fig.1F; Extended Data Fig.1B; Supplementary Table 1; also: 210 
Supplementary Information file). Based on these data, we focused on the 211 
CNIO molecule CDK8/19i-ETP-47799, which was the most effective at improving 212 
mouse PSCs, and we will refer to it simply as CDK8/19i (Fig.1A,B and Extended 213 
Data Fig.1A; for the structure and characterization of this inhibitor, and 214 
comparison with other inhibitors used in this study: Supplementary Table 1; 215 
Supplementary Information). In addition to the improvements in Nanog-GFP 216 
profile and colony morphology mentioned before, the effect of CDK8/19i on 217 
mouse PSCs resembled 2i in three additional ways: (i) it was observed in serum- 218 
and serum-free based media (Fig.1A and Extended Data Fig.1A); (ii) it was 219 
reversible upon CDK8/19i-withdrawal with kinetics similar to that of 2i-removal 220 
(Extended Data Fig.1C); and, (iii) upon removal of LIF or inhibition of LIF-221 
signaling with a JAK inhibitor, the presence of CDK8/19i delayed downregulation 222 
of Nanog-GFP expression (Extended Data Fig.1D,E). We conclude that 223 
inhibition of Mediator kinase CDK8/19 shifts mouse PSC morphology and Nanog 224 
expression towards their characteristic status in the naïve state18,23,29. 225 
 226 
Exploring genetic validation, depletion via shRNA-knockdown of CDK8, 227 
CDK19, but most successfully, their regulatory partner cyclin C (CCNC; essential 228 
for full kinase activity8), led to upregulation of Nanog expression and naïve-like 229 
colony morphology (Fig.1G and Extended Data Fig.1F,G). In another genetic 230 
approach, CDK8 and CDK19 double-knockout (dKO) mouse PSCs were 231 




generated (Extended Data Fig.1H-K). CDK8/19-dKO PSCs could self-renew 232 
indefinitely, but did not acquire naïve morphological features or Nanog 233 
upregulation, and no longer responded to CDK8/19-inhibitors (Extended Data 234 
Fig.1L,M). This suggested that the beneficial effects observed may require the 235 
physical presence of the inactive-kinase. In agreement, we found that CDK8/19-236 
dKO PSCs reconstituted with exogenous CDK8 rescued the ability to respond to 237 
the CDK8/19 inhibitor molecule, observed by naïve morphological features and 238 
Nanog, Klf4, and Oct4 upregulation (Extended Data Fig.1L,M). Moreover, 239 
CDK8/19-dKO PSCs reconstituted with a CDK8-kinase dead mutant (CDK8-KD; 240 
D173A) displayed homogenous naïve colony morphology, high expression of 241 
naïve-state markers (Fig.1H-M), and downregulation of Fgf5, a key marker of the 242 
primed state18,19,23 (Fig.1J); all without the need of any chemical inhibitor and 243 
despite maintaining active MEK-ERK signaling (Fig.1K). Thus, CDK8/19-dKO 244 
cells expressing CDK8-KD phenocopy the effects of chemical inhibition of 245 
CDK8/19. Lastly, post-implantation epiblast stem cells (EpiSC; cultured with 246 
FGF2/Activin) are a more developmentally advanced primed state than mouse 247 
PSCs in serum/LIF18,19. Interestingly, EpiSC exogenously expressing CDK8-KD 248 
lost Fgf5, upregulated Nanog, Rex1, and Klf4, and formed dome-shaped colonies 249 
with high alkaline phosphatase staining, altogether characteristic of conversion to 250 
the naïve state (Fig.2A and Extended Data Fig.2A). In summary, CDK8 kinase 251 
inhibition is sufficient to promote key characteristics of naïve pluripotency, despite 252 
the continued presence of MEK-ERK signaling. 253 
 254 
Long-term culture of mouse PSCs (>10 passages) in CDK8/19i maintained 255 
their upregulation of naïve features, including colony morphology, high alkaline 256 
phosphatase, Nanog-GFPhigh, high endogenous Nanog, high ICAM1 cell surface 257 
expression, and nuclear localization of TFE321,24,32–34 (Fig.2B-D and Extended 258 
Data Fig. 2B,C). Long-term CDK8/19i-adapted PSCs displayed typical 259 
developmental capacity following inhibitor withdrawal, specifically, retinoic-acid-260 
induced differentiation, embryoid body cardiac centre formation, spheroid 261 
polarization and lumenogenesis35, generation of teratomas containing three germ 262 
layers, and robust chimera contribution after morula aggregation and blastocyst 263 
micro-injection assays (traced by constitutive GFP or RFP) evaluated at E4.5, 264 




E7.5, E14.5, and fully-developed adults which subsequently completed germline 265 
transmission (Fig.2D-I and Extended Data Fig.2D-F). Of note, continued 266 
presence of CDK8/19i impaired the early developmental events35 of polarization 267 
and lumenogenesis in vitro (Fig.2E), an observation discussed further below. 268 
Thus, PSCs long-term adapted to CDK8/19i maintain their upregulation of naïve 269 
features, their self-renewal, and their developmental capacity. 270 
 271 
CDK8/19i induces and stabilizes the naïve state in human PSCs 272 
We tested CDK8/19i on human stem cell identity. STAT3 overexpression plus 273 
2i/LIF induces the human naïve state36, and we observed that CDK8/19i could 274 
replace 2i in this system (Fig.2J). Even in the absence of STAT3 overexpression, 275 
other transgenes, or chemicals, CDK8/19i treatment progressively converted 276 
human iPS colonies from flat and primed-like, to dome-shaped naïve-like bi-277 
refringent morphology. This was observed for a total of 7 human PSC lines 278 
treated with 0.4µM or 1.1µM CDK8/19i/LIF for 2-3 weeks (Fig.2K and Extended 279 
Data Fig.2G), including human iPSCs carrying a specific HERVH-GFP reporter 280 
insertion that marks human naïve cell identity37 (Fig.2K and Extended Data 281 
Fig.2H). A 2i-based chemical cocktail combined with selection by cell-sorting 282 
(abbreviated as 2i p38iJNKi) induced naïve colony morphology, as expected33,37, 283 
with homogeneous high HERVH-GFP (Extended Data Fig.2H). Interestingly, 284 
treatment with CDK8/19 inhibitors (CNIO-47799 or SnxA) also produced 285 
morphological conversion and increased GFP, similar to 2i p38iJNKi (Fig.2L and 286 
Extended Data Fig.2H). The changes induced by CDK8/19 inhibition were 287 
gradual, required no selection upon passage (sorting or manual picking), required 288 
no additional supplements except rhLIF, and were stable in the continuous 289 
presence of the inhibitor. In contrast, CDK7 inhibition failed to change colony 290 
morphology or GFP fluorescence, and produced cell death (Extended Data 291 
Fig.2H). Culture of human PSCs in CDK8/19i increased their clonogenicity, 292 
alkaline phosphatase intensity, and pluripotency markers32–34,38 NANOG, OCT4, 293 
SSEA4, TRA1-81, TFCP2L1, and KLF17 (Fig.2M, 3A, and Extended Data 294 
Fig.2I and 3A-C).  MYC, known to be reduced in naïve cells25,32, was also 295 
reduced in cells maintained in CDK8/19i (Fig.3A). Therefore, similar to 296 




observations in mouse PSCs above, treatment of human PSCs with CDK8/19i 297 
establishes features characteristic of the naïve state. 298 
 299 
Developmental potential of CDK8/19i-adapted human PSCs 300 
Chemical induction of the human naïve state can trigger genomic instability, 301 
severely impairing developmental potential24,39. We found that CDK8/19i-adapted 302 
human PSCs (five lines) had normal karyotype over >16 passages (Extended 303 
Data Fig.3D) and, upon inhibitor withdrawal, maintained the capacity to 304 
contribute towards all three embryonic germ layers by embryoid body 305 
differentiation in vitro and by teratoma assay in vivo (Fig.3B-D, and 306 
Supplementary Table 1), comparable to control primed cells. Preimplantation 307 
interspecies chimerism tests for naïve-specific properties, namely, capacity for 308 
clonal survival in a host embryo40,41. We tested CDK8/19i-adapted human iPSCs 309 
carrying a constitutive Tomato-red marker for human-rabbit interspecies 310 
chimerism by micro-injecting them into E2.5 rabbit morulae. Interestingly, the 311 
presence of human cells (Tomato-positive) was detected 72h later in up to 50% 312 
of the injected rabbit blastocysts (Fig.3E). In contrast, human PSC in the primed 313 
state were unable to integrate or survive in rabbit embryos (0/24 rabbit embryos), 314 
similar to previous reports for primed state human PSCs within the embryos of 315 
mice, pigs, and cattle40,41. In summary, long-term adaptation of human PSCs to 316 
CDK8/19i stabilizes naïve pluripotency while preserving their developmental 317 
potential. We conclude that the role of CDK8/19 in pluripotency is conserved in 318 
mouse and humans, and therefore presumably, across mammals. 319 
 320 
CDK8/19i resets the transcriptome and proteome similar to 2i 321 
Using RNA-seq, we compared global gene expression in mouse PSCs long-term 322 
adapted to CDK8/19i versus 2i. Overall, CDK8/19i altered gene expression with a 323 
magnitude similar to 2i conditions, and with a highly significant overlap in the 324 
identity and biological functions of genes up- or down-regulated, in both serum-325 
containing and serum-free media (Fig.4A, Extended Data Fig.3E,F, and 326 
Supplementary Table 2). Compared to control primed conditions, naïve 327 
pluripotency markers were enhanced in CDK8/19i and 2i (Fig.4B and Extended 328 




Data Fig.3G), while differentiation markers were globally downregulated in 329 
CDK8/19i and 2i (Supplementary Table 2). 330 
 331 
 Endogenous retrovirus (ERV) expression is highly stage-specific during 332 
mammalian pre-implantation and precisely defines naïve and primed PSC 333 
identity42–46. The transcriptomic overlap between CDK8/19i or 2i treatments 334 
extended to ERVs, with similar viral families significantly up- or downregulated in 335 
mouse PSCs (Fig.4C and Supplementary Table 2). In particular, LINE L1 336 
families, each with thousands of copies across the genome, were regulated in 337 
close parallel, displaying highly similar alteration in CDK8/19i and 2i-naïve states 338 
(Extended Data Fig.3G,H). Another aspect of the plasticity of mouse PSCs is 339 
their ability to transition to a 2-cell-like (2C) state, specifically marked by hyper-340 
activation of the MERVL family of ERVs and by Zscan4c expression46,47. 341 
Stabilization of the naïve state with 2i impairs the 2C-like fluctuation46,47. This was 342 
also observed in CDK8/19i-treated PSCs, using multiple 2C-markers, including 343 
MERVL and Zscan4c, and MERVL-Tomato and Zscan4c-eGFP 2C-reporter 344 
models (Fig.4D, and Extended Data Fig.3I-M and 4A-C). Finally, our CDK8/19i 345 
and 2i transcriptomic data correlated with published transcriptomes48–51 from 346 
independent studies of 2i-naïve mouse PSCs and the transcriptome of E4.5 347 
epiblast single-cells52 (Fig. 4E, and Extended Data Fig.4D,E). 348 
 349 
RNA-seq analyses of human PSCs adapted to CDK8/19i, or a 2i-based 350 
naïve cocktail, overlapped significantly (Fig.4F; Supplementary Table 3). 351 
Markers of human and primate pre-implantation epiblasts and in vitro naïve 352 
human PSCs32–39 were upregulated by CDK8/19i, while differentiation markers 353 
were repressed53–59 (Fig.4G, Extended Data Fig.4F-J, and Supplementary 354 
Table 3). Moreover, the global human ERV transcriptomes of CDK8/19i- or 2i-355 
adapted cells overlapped extensively, including upregulation of the SVA, LTR7, 356 
and HERV families (Fig.4H-J and Supplementary Table 3), consistent with 357 
reports of ERV expression in human and primate naïve PSCs and pre-358 
implantation epiblast43–45. Lastly, we observed high correlation between 359 
CDK8/19i-adapted human PSCs and RNA expression datasets from seven 360 




independent studies in human and primate PSCs in the in vitro naïve state and in 361 
embryo naïve epiblast single-cell analyses39,53–60 (Fig.4K). 362 
 363 
 While PSC plasticity has been explored in terms of RNA expression, its 364 
proteome remains relatively ill-defined. We analyzed the proteome of mouse 365 
PSCs in control serum/LIF versus 2i-naïve or CDK8/19i-adapted conditions. 366 
Across five mouse PSC lines, CDK8/19i altered the expression levels of 465 367 
proteins, 159 (34%) of which changed in the same direction in 2i conditions 368 
(Fig.4L,M; Extended Data Fig.5A,B; Supplementary Table 4). Importantly, 369 
among the overlapping changes in both 2i-naïve and CDK8/19i conditions, we 370 
noted key pluripotency regulators such as KLF4, and metabolic pathways such 371 
as oxidative phosphorylation, featured amongst the most-upregulated; while 372 
LIN28A, MYC-target genes, and differentiation markers, were down-regulated 373 
(Fig.4M; Extended Data Fig.5C; Supplementary Table 4). In addition, 374 
proteomic changes in 2i and CDK8/19i significantly correlated with the 375 
transcriptomic changes observed (Extended Data Fig.5D,E). 376 
 377 
In summary, CDK8/19i upregulates pluripotency markers, reshapes the 378 
endogenous retroviral transcriptome, and represses differentiation markers, in a 379 
manner similar to the transcriptomic and proteomic resetting observed in 380 
previous studies of naïve pluripotency, in vitro and in vivo, in mouse and in 381 
human. 382 
 383 
CDK8/19i does not reset global DNA methylation levels 384 
Many 2i-based chemical cocktails induce global DNA hypomethylation, both in 385 
mouse and human PSCs21. This has been attributed to MEK-dependent 386 
stabilization of UHRF1, a critical factor for the recruitment of DNMT1 to DNA61. 387 
Importantly, the pattern of demethylation induced by 2i diverges significantly 388 
compared to the pre-implantation naïve epiblast state, and is associated with 389 
PSCs exhibiting genomic instability, chromosomal defects and loss of 390 
pluripotency24,39,62,63. Recent 2i-variant cocktails (with partial MEK-inhibition) offer 391 
the advantage of largely preserving global DNA methylation62–64. Importantly, 392 
neither mouse nor human CDK8/19i-adapted PSCs showed evidence of global 393 




DNA hypomethylation (Fig.5A,B). In support of global DNA hypomethylation, 2i 394 
or MEK-inhibition-alone, induced demethylation of LINE L1 repeat regions 395 
(Fig.5C), and major satellite regions (Extended Data Fig.5F), but had no effect 396 
on methylation of IAP repeats (Extended Data Fig.5G), all as previously 397 
reported65. In contrast, CDK8/19i did not reduce methylation at any of these 398 
mouse repeat elements (Fig.5C; Extended Data Fig.5F,G), or UHRF1 levels 399 
(Supplementary Table 4). Thus, CDK8/19i induces naïve features in the 400 
absence of global DNA hypomethylation, and this is likely due to its lack of MEK 401 
inhibition (Fig.2), or Uhrf1 downregulation. By not recapitulating the partial 402 
demethylation of the naïve epiblast, CDK8/19i has the advantage of preserving 403 
chromosomal stability and pluripotency upon cell expansion (Fig.2,3), which is 404 
particularly relevant for naïve human PSCs. This is in line with variant media 405 
cocktails based on minimizing MEK-inhibition both in mouse and human naïve 406 
PSCs62–64. 407 
 408 
 X-chromosome reactivation status is another molecular signature reported 409 
in human naïve pluripotency during MEK-inhibition21,66,67, which may be inferred 410 
by assessing XIST RNA expression in female cells. However, analysis by qPCR 411 
revealed very low XIST expression in our primed human PSCs (Extended Data 412 
Fig.5H), suggesting that erosion of X-silencing may have already occurred in the 413 
parental cells under primed conditions, as observed previously67. Notably, some 414 
2i-based cocktails reactivate XIST expression even in X-eroded primed human 415 
PSCs66,67, but this was not the case of our CDK8/19i-adapted cells (Extended 416 
Data Fig.5H). In summary, CDK8/19i treatment does not recapitulate the 417 
reactivation of XIST in X-eroded primed cells, indicating another distinction with 418 
most human media cocktails based on MEK-inhibition. 419 
 420 
CDK8/19i induces phospho-changes similar to 2i 421 
We assessed the phospho-proteome of mouse PSCs just 15min after exposure 422 
to CDK8/19i or 2i, to explain their phenotypic similarity. Strikingly, out of 622 423 
phospho-sites altered, 495 (79.6%) were similarly regulated by CDK8/19i and 2i 424 
(Fig.5D,E). The co-regulated phospho-sites occurred on proteins heavily 425 
enriched for functions in transcriptional regulation and key stem cell signaling 426 




pathways (Fig.5E; Extended Data Fig.5I; Supplementary Table 5). Note, 427 
CDK8/19i did not inhibit the kinase activity of purified recombinant GSK3 or MEK 428 
(Supplementary Table 1), and CDK8/19i did not reduce the relative levels of 429 
phospho-ERK (Fig.1K; Fig.5F,G; Extended Data Fig.5J). However, 2i-treatment 430 
reduced CDK8/19 kinase activity (Fig.5F; Extended Data Fig.5K), and 431 
moderately downregulated CDK8 protein levels (Extended Data Fig.5L). These 432 
data suggest that CDK8/19 inhibition occurs downstream of 2i, such that both 433 
treatments result in highly overlapping phospho-site changes. 434 
 435 
CDK8/19i resets global RNA Pol II loading similar to 2i 436 
2i and CDK8/19i induce similar phospho-proteomic changes (converging on 437 
transcriptional machinery) and similar transcriptomic changes. Thus, to 438 
understand how CDK8/19-inhibition phenocopies the transcriptome of 2i-induced 439 
naïve pluripotency, we investigated their global regulation of RNA Pol II 440 
abundance on chromatin by ChIP-seq in mouse PSCs. Overall, total- and Ser5-441 
phosphorylated-RNA Pol II genomic distribution was consistent with published 442 
resources23,68,69 (ENCODE: https://www.encodeproject.org/). However, we 443 
observed that 2i globally increases RNA Pol II binding to promoters (Fig.5H,I; 444 
Extended Data Fig.6A-C), which was confirmed by re-analyzing independent 445 
data23,69. Remarkably, this global effect of 2i was phenocopied by CDK8/19i, 446 
regarding both total- and Ser5-phosphorylated-RNA Pol II (Fig.5H,I; Extended 447 
Data Fig.6A-C). We measured RNA Pol II abundance in the promoter, gene 448 
body and transcription termination site (TTS) for each gene (Fig.5J; Extended 449 
Data Fig.6D; Supplementary Table 6). Consistent with previous analyses in 450 
mouse PSCs23,68, most genes (90%) possessed a promoter to gene body loading 451 
ratio >2.0 (Fig.5J; Supplementary Table 6). Comparison of RNA Pol II ratios 452 
between the promoter, gene body, or termination sub-regions of each gene 453 
indicated that 2i induces an increase in RNA Pol II binding selectively to the 454 
promoter region (Fig.5J; Extended Data Fig.6D). Importantly, this was 455 
recapitulated by CDK8/19i, increasing RNA Pol II binding to promoters at a 456 
similar magnitude to that observed in 2i-induced naïve pluripotency, following a 457 
gene-specific pattern (Fig.5J; Fig6A-F; Supplementary Table 6). Therefore, 2i- 458 
and CDK8/19i-induced naïve pluripotency are accompanied by widespread 459 




accumulation of RNA Pol II abundance at promoters. We also observed a 460 
correlation between changes in RNA Pol II promoter abundance in 2i or in 461 
CDK8/19i conditions, and changes in mRNA expression for each gene 462 
(Extended Data Fig.6E-I). In summary, gene-specific changes in RNA Pol II 463 
promoter loading may explain a significant proportion of the mRNA expression 464 
profile characteristic of 2i- or CDK8/19i-induced naïve pluripotency. 465 
 466 
CDK8/19i and 2i trigger activation of super-enhancers 467 
The primary role of Mediator is at enhancers, regulating RNA Pol II recruitment to 468 
promoters4–6. Using published ChIP-seq datasets2,3 (Supplementary Table 7; 469 
Source Data), we confirmed that CDK8/19 was enriched at promoter, typical 470 
enhancer (TE) and super-enhancer (SE) regions as previously defined in mouse 471 
PSCs2 (Fig.6G; Extended Data Fig.7A-C). A strong correlation existed between 472 
the abundance of CDK8/19, Mediator subunits, and other factors critical for 473 
enhancer activity1,6 (such as, p300, CBP, Pol II, or BRD4) (Extended Data 474 
Fig.7D); the highest levels of CDK8/19 occurred within SE-regions (Fig.6G; 475 
Supplementary Table 7; Source Data); and lastly, putative target genes 476 
proximal to genomic CDK8/19 binding loci were highly enriched in 477 
preimplantation functions characteristic of pluripotent cell identity (Extended 478 
Data Fig.8A-C). Thus, we hypothesized that in mouse PSCs, CDK8/19-inhibition 479 
might act through Mediator to trigger changes in enhancer activity, explaining the 480 
observed increase of RNA Pol II loading at promoters and regulation of 481 
pluripotent states. Since CDK8/19 protein was particularly enriched at SE-482 
regions, we examined the impact of CDK8/19i on SE function. Enhancers contain 483 
RNA Pol II which transcribes enhancer-RNAs (eRNAs), a process that faithfully 484 
reflects enhancer activity4,8,70. Therefore, we measured the effect of CDK8/19i or 485 
2i on the levels of RNA Pol II and eRNAs at SEs. Importantly, the abundance of 486 
RNA Pol II was selectively increased at CDK8/19 binding sites and, accordingly, 487 
RNA Pol II recruitment was also preferentially increased at SEs compared to TEs 488 
(Fig.6H,I; Extended Data Fig.8D). Consistent with this, mouse PSCs treated 489 
with 2i or CDK8/19i displayed elevated enhancer-derived eRNA levels, and RNA 490 
Pol II abundance, within enhancers specific for the naïve-state71 (Fig.7A; 491 
Extended Data Fig.8E,F). Induction of naïve-specific eRNAs and naïve marker 492 




genes was an early event, occurring within 48h of adding 2i or CDK8/19i, and it 493 
was rapidly reversible (Fig.7A; Extended Data Fig.8G). Lastly, consistent with 494 
naïve-specific enhancer activation, the expression levels of SE target-genes were 495 
preferentially upregulated in both 2i and CDK8/19i (Fig.7B,C; Extended Data 496 
Fig.8H). We conclude that in PSCs, CDK8/19i and 2i hyper-activate existing SE, 497 
and upregulate SE target-genes, in a manner which reinforces naïve 498 
pluripotency. 499 
 500 
CDK8/19 inhibition compensates BRD4 inhibition 501 
Loss of Mediator function preferentially decreases expression of enhancer target 502 
genes across multiple cell types4–6,26–28. In particular, BRD4-inhibition in primed 503 
state PSCs decreases the ability of Mediator to recruit RNA Pol II, and this 504 
results in loss of Mediator-driven transcription, collapse of pluripotency gene 505 
expression, and differentiation27,28 (Fig.1A). Compared to primed PSCs, naïve 506 
PSCs are highly resistant to the decreased Mediator activity and enhancer 507 
destabilization induced by BRD4-inhibition28. Interestingly, mouse PSCs lacking 508 
endogenous CDK8 and CDK19 and reconstituted with kinase-dead CDK8 were 509 
resistant to enhancer destabilization by BRD4-inhibition for 10 passages (>3 510 
weeks), maintaining naïve morphology, and high expression of alkaline 511 
phosphatase, naïve-specific pluripotency markers, and naïve-specific eRNAs, 512 
similar to 2i-naïve PSCs (Fig.7D,E; Extended Data Fig.8I,J). Thus, PSCs 513 
expressing kinase-dead CDK8 phenocopy the robust resistance to enhancer 514 
destabilization characteristic of 2i-naïve PSCs. 515 
 516 
Roles of CDK8/19 during early embryonic development 517 
Given our observations that CDK8/19 inhibition stabilizes naïve pluripotency, we 518 
investigated CDK8/19 function during early embryonic development. We focused 519 
on CDK8, which we found highly expressed compared to CDK19, both in mouse 520 
and human PSCs (Extended Data Fig.1K,9A). Using a CDK8-specific antibody 521 
(Extended Data Fig.1J), we detected CDK8 protein from the mouse zygote to 522 
morula (Extended Data Fig.9B). Consistent with this, CDK8-knockout zygotes 523 
cannot progress beyond 4-8 cell stage72, and we observed that CDK8/19i 524 




impaired the progression of 1-cell zygotes to the 2-cell stage (Extended Data 525 
Fig.9C). Therefore, CDK8 activity is essential for the zygote to morula transition. 526 
 527 
Next, we investigated the role of CDK8 post-morula. CDK8 mRNA 528 
expression declines until blastocyst stage, both in mouse and human pre-529 
implantation embryos (Extended Data Fig.9D-F). CDK8 protein expression per 530 
cell was homogenous in the mouse inner cell mass (ICM) at E3.5 (Fig.8A,B). 531 
Interestingly, at E4.5, when the ICM segregates into the naïve epiblast and the 532 
primitive endoderm (PE), CDK8 protein levels diverged, with lower levels in 533 
epiblast compared to PE (Fig.8A,B; Extended Data Fig.10A). This pattern was 534 
transient, and it reversed in post-implantation epiblast at E5.5 (Fig.8A,B; 535 
Extended Data Fig.10A). To further document that CDK8 levels are reduced in 536 
the naïve epiblast, embryos were cultured from E3.5-E4.5 with MEK inhibitor 537 
(MEKi), which blocks PE formation, and permits only development of naïve 538 
epiblast73,74. As expected, in MEKi, the ICM contained only naïve epiblast cells 539 
and not PE, facilitating observation of their reduced CDK8 expression (Fig.8C,D). 540 
Also, the CDK8 binding partner and essential activating subunit cyclin C altered 541 
its nuclear-cytoplasmic ratio during this developmental window. Specifically, E4.5 542 
epiblast contained significantly less nuclear cyclin C than E5.5 in vivo (Extended 543 
Data Fig.10B,C), and a similar pattern was observed comparing 2i-naïve versus 544 
primed state PSCs in vitro (Extended Data Fig.10D). In summary, the 545 
emergence of naïve pluripotency during embryo development, at E4.5, coincides 546 
with decreased CDK8 expression and decreased availability of its essential 547 
subunit cyclin C. This parallels the effect of MEKi on CDK8 expression, and 548 
stabilization of naïve epiblast identity in PSCs in vitro (Extended Data Fig.5). 549 
 550 
We wondered whether inhibition of CDK8/19 affects the emergence of 551 
naïve pluripotency. Similar to MEKi, CDK8/19i treatment during E3.5-E4.5 did not 552 
interfere with embryo naïve epiblast development (Fig.8E-G) and allowed the 553 
derivation of PSC lines. In contrast to MEKi, CDK8/19i permitted PE formation 554 
(Fig.8E-G). This suggests that the critical roles of MEK for PE segregation are 555 
independent of CDK8/19, and corresponds with our observation that MEK activity 556 
is unaffected by CDK8/19i (Fig.5F,G). 557 





Finally, we examined the importance of CDK8/19 activity during pre-559 
implantation to post-implantation epiblast developmental progression. We 560 
focused on lumen formation within the epiblast, which marks the initiation of 561 
morphogenesis downstream of naïve pluripotency exit35. We found that CDK8/19i 562 
treatment during E4.5-E5.5 impaired embryo epiblast lumenogenesis (Fig.8H; 563 
Fig.2E for spheroids). This indicates a requirement for CDK8/19 activity to 564 
support epiblast development, from the naïve pre-implantation to primed post-565 
implantation embryonic stages, consistent with the significant elevation we 566 
observed in CDK8 expression at this time (Fig.8A,B; Extended Data Fig.9E). 567 
 568 
These data suggest that CDK8/19 expression in early embryonic 569 
development mirrors its function: the transition from zygote to morula, and the 570 
formation of the post-implantation epiblast require CDK8/19 activity; while the 571 
intervening naïve ICM has low CDK8 expression and reduced nuclear cyclin C 572 




We uncover a role for the Mediator-kinases CDK8/19 in defining the equilibrium 577 
between naïve and primed pluripotent states, in both mouse and human 578 
pluripotent cells. Collectively, our data point towards the following model: 2i and 579 
CDK8/19i rapidly induce a highly overlapping set of phospho-changes focused on 580 
the transcriptional machinery, triggering enhancer hyperactivation, global 581 
increase in RNA Pol II recruitment to promoters, and resetting of gene 582 
expression. This includes the upregulation of enhancer-derived RNAs (eRNAs), 583 
and the resetting of endogenous retroviral and repeat element expression, to 584 
coordinate this cell identity conversion. Further evidence supporting 585 
transcriptional stabilization of naïve pluripotency includes repression of the 2C 586 
fluctuation in PSC identity, similar to 2i. Thus, the ability of 2i and CDK8/19i to 587 
induce naïve features appears to originate from their common effect on Mediator 588 
and RNA Pol II transcriptional activity. In support, super-enhancers interact with 589 
more target promoters75, engage in more long-range interactions75, and display 590 




increased H3K27ac76, in the naïve state versus primed. Our model agrees with 591 
the concept that transitions in cell identity are driven by early reconfiguration of 592 
the active enhancer network, which resets the transcriptional machinery to the 593 
new program70,71,77. 594 
 595 
Evidence presented here suggests a signaling hierarchy; in particular, 596 
MEK inhibition results in CDK8/19 inhibition, while inhibition of CDK8/19 does not 597 
affect MEK activity. Accordingly, we observe that (i) the ability of MEK/GSK 598 
inhibition (2i) to induce naïve features in PSCs in vitro is recapitulated by 599 
CDK8/19i; (ii) 2i and CDK8/19i exhibit a 79.6% overlap in downstream phospho-600 
changes; (iii), CDK8/19 down-regulation coincides with the emergence of naïve 601 
state in vivo, when MEK-ERK signaling is decreased18,19; and, (iv) both MEK-602 
ERK activation18,19,30,73,74 and CDK8/1978,79 drive post-implantation epiblast 603 
differentiation, a process we found impaired by CDK8/19i, and a period where 604 
CDK8 was up-regulated. Thus, we propose CDK8/19-inhibition is a common 605 
downstream feature of naïve-inducing media cocktails. Further studies will 606 
elucidate how MEK-ERK signaling regulates CDK8/19-Mediator activity in PSCs. 607 
Intriguingly, Mediator hyperactivation via CDK8/19-inhibition triggers cancer cell 608 
death14, while we find a similar approach reinforces naive pluripotent identity. 609 
Cancer cells commonly develop novel oncogenic SEs, becoming addicted to a 610 
defined range of enhancer-driven transcription that appears sensitive to 611 
perturbation9,80. This provides an interesting parallel with MEK inhibition, which is 612 
also detrimental to many cancer cells, but beneficial to pluripotency.  613 
 614 
Stabilization of the human naïve pluripotent state in vitro is challenging 615 
and remains to be optimized21,24. Our understanding of stem cell identity 616 
indicates a continuum of molecular changes along a spectrum from naïve to 617 
primed states, which also reflects the developmental path in early 618 
embryos18,19,21,22. Where does CDK8/19i position PSCs along this gradient? We 619 
find that CDK8/19 inhibition recapitulates the majority of molecular characteristics 620 
associated with primed to naïve transition. However, other molecular features 621 
associated with the more-naïve end of this spectrum are not recapitulated by 622 
CDK8/19 inhibition, particularly, global DNA hypo-methylation, X-chromosome 623 




reactivation66,67, and SSEA4 down-regulation24,39. Achieving these last features of 624 
naïve pluripotency appears to come at a price. Naïve-inducing media cocktails 625 
dependent on MEK-inhibition generate harmful side effects, specifically acute 626 
chromosomal instability and imprinting erasure24,39,62,63. Other cocktails do not 627 
downregulate SSEA4, produce modest DNA demethylation, and are not 628 
associated with genomic instability24,33,64. Similarly, CDK8/19i installs many naïve 629 
features in human cells while maintaining SSEA4, DNA global methylation and 630 
genomic stability. CDK8/19i-treated cells retain normal karyotype after prolonged 631 
culture. We suggest these important differences are due to CDK8/19i not 632 
impinging directly on MEK-signaling.  633 
 634 
In summary, CDK8/19i stimulates Mediator recruitment of RNA Pol II. This 635 
effectively hyper-activates enhancers and stabilizes the transcriptional program 636 
of naïve pluripotent cell identity. Thus, chemical inhibition of CDK8/19 may help 637 
to solve remaining challenges in unstable human naïve PSC culture. Similarly, 638 
these principles of stabilizing cellular identity may apply to other contexts of 639 
cellular plasticity.640 
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FIGURE LEGENDS 906 
 907 
Figure 1:  908 
An inhibitor screen for promotion of PSC naïve state identifies a distinct 909 
role for Mediator kinase activity. 910 
(A) FACS: effect of indicated treatments on Nanog expression (Nanog-GFPhigh) 911 
per cell, using mouse Nanog-GFP knockin reporter PSC cell line29 in standard 912 
serum/LIF base media. Mean+/-SD of n=4 independent experiments. 913 
(B) FACS histogram of Nanog-GFP expression. Nanog-GFPLow and Nanog-914 
GFPHigh cell populations in serum/LIF population (grey). Dotted line: threshold 915 
where >95% cells are Nanog-GFPHigh in 2i-naïve culture condition. Data 916 
representative of 3 experiments. 917 
(C) PSC colony morphology in indicated treatments. Brightfield and Nanog-GFP 918 
shown. Data representative 6 experiments. 919 
(D,E) Endogenous Nanog mRNA (D), or protein (E), expression levels in mouse 920 
PSCs adapted to indicated conditions. Data representative of n=3 experiments, 921 
Mean+/-SD, *P < 0,05, t-test, unpaired, two-tailed. 922 
(F) Phosphorylation levels of CDK8-target STAT1 Ser727. HERVH human iPS 923 
PSCs treated with CDK8/19i concentrations for 3h +/- simultaneous induction of 924 
STAT1-Ser727P by γ-interferon for 3h. Data representative of 2 experiments. 925 
(G) Cell morphology and qRT-PCR of mouse PSCs following 7d of shRNA-926 
mediated knockdown of CDK8, CDK19, CyclinC (CCNC). Data: Mean of 2 927 
experiments. 928 
(H,I) Cell morphology and alkaline phosphatase staining (H), FACS analysis of 929 
endogenous NANOG and OCT4 protein levels (I), in CDK8/19-dKO iPSCs stably 930 
expressing pMSCV-Empty or pMSCV-CDK8-Kinase Dead (CDK8-KD). Data 931 
representative of 3 independent clones. 932 
(J,K) qRT-PCR (J; Data: Mean+/-SD from n=3 independent clones), and 933 
Western blot analysis of protein expression (K; Data: representative of 2 934 
 
 
experiments) in WT iPSCs, or CDK8/19-dKO iPSCs stably expressing pMSCV-935 
Empty or pMSCV-CDK8-KD, adapted to the indicated media conditions. 936 
(L) Alkaline phosphatase staining. Cells fixed and stained at 14d after retroviral 937 
expression of pMSCV-Empty or pMSCV-CDK8-KD. Staining intensity was scored 938 
visually for each colony, using ten fields of view. Data represent n=3 939 
experiments, Mean+/-SD. 940 
(M) Immunofluorescence in CDK8/19-dKO iPSCs expressing pMSCV-CDK8-KD-941 
puro-IRES-GFP. Data representative of 4 experiments. 942 
Scale bars 100µm. See also Supplementary Table 1 and Supplementary 943 
Information file for inhibitor characterization. 944 
 945 
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Figure 2:  947 
Positive effect of long-term CDK8/19i on PSC self-renewal and pluripotency 948 
(A) Morphology and mRNA expression of mouse EpiSC expressing pMSCV-949 
Empty or pMSCV-CDK8-KD, then 7d in EpiSC media, or standard ES media 950 
serum/LIF. Plots: Mean+/-SD, n=3 experiments. Scale bar 100µm. 951 
(B,C) Clonogenicity of mouse PSCs. Nanog-GFP PSCs were FACS-sorted 1-952 
cell/well, cultured 7d, then Alkaline phosphatase stained (B), or scored for 953 
Nanog-GFP intensity (C), to assess pluripotent status/colony, in either standard 954 
media serum/LIF, 2i-naïve, or CDK8/19i conditions. Data: representative of 3 955 
experiments. 956 
(D,E) Differentiation capacity of mouse PSCs previously adapted to serum/LIF, 2i 957 
or CDK8/19i. (D), PSCs differentiated as indicated in 2D culture. PSC exit from 958 
pluripotency (Nanog down-regulation) and differentiation (Nestin upregulation) by 959 
qRT-PCR. Data: Mean of 2 experiments. (E) Pluripotency exit assessed by 960 
immunofluorescence after PSC culture in 3D-matrigel/LIF +/-CDK8/19i, to 961 
observe early epiblast development (rosette formation and lumenogenesis) in 962 
PSC-spheroids35. “Disorganized”: differentiatiation failure. Data: representative of 963 
3 experiments, n=30 spheroids/condition; T-test, unpaired, two-tailed, *P=0,0097. 964 
Scale bar 10µm. 965 
(F-I) In vivo assays of developmental capacity. Mouse CDK8/19i-PSCs 966 
constitutively-labelled (ROSA26-GFP or Tg.CAG-Katushka) were aggregated 967 
with, or micro-injected into, host E2.5 morulae. Embryo chimerism was assessed 968 
visually: E4.5 blastocyst, n=10 (F); E6.5 egg cylinder, n=10 (G); E14.5, n=2 (H); 969 
and peri-natal E19.5, n=4 (I). In (I), 3 male adult chimeras (below left, percent 970 
chimerism by coat colour, indicated) displayed germline transmission, generating 971 
3 litters (below right, coat colour confirmed germline transmission per litter). 972 
Scale bars, F: 25µm; G: 100µm; H: 1mm; I: 1mm. 973 
(J) Induction of naïve colony morphology in human OSCAR ES cells. Tamoxifen-974 
inducible consitutively-active STAT3/LIF/2i (TL2i)36, or substituting CDK8/19i for 975 
2i (TLCDK8/19i). Data: representative of 3 experiments. Scale bar 100µm. 976 
 
 
(K,L) (K) Induction of naïve colony morphology in 3 human PSC lines; primed or 977 
+14d CDK8/19i. Scale bar 100µm. (L) Cytometry of HERVH-GFP intensity/cell in 978 
human PSCs; primed or 14d CDK8/19i culture. Panels K and L, representative of 979 
>5 experiments. 980 
(M) Western blots of pluripotency markers in human PSCs; primed or cultured 981 
14d with 2i-based or CDK8/19i-based media. SMC1, loading control. 982 
 983 
 984 
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Figure 3:  986 
Positive effect of long-term CDK8/19i on human PSC self-renewal and 987 
pluripotency 988 
(A) Immunofluorescence. Pluripotency markers; human PSCs cultured as 989 
indicated. Data representative of 2 experiments. Scale bar 100µm. 990 
(B) Embryoid body differentiation assay using endoderm-directed, or caridac-991 
directed protocols with human PSCs. Plots: mRNA expression of pluripotency or 992 
embryonic germ layer markers by qRT-PCR, Mean of n=4 technical replicates. 993 
Data for H9 cell line shown, representative of two experiments (human PSC lines 994 
H1 and H9: Source Data and Supplementary Information summarize all tested 995 
lineage markers, determined by qRT-PCR (17) or immunofluorecence (6). 996 
(C,D) Human PSCs adapted to primed or CDK8/19i, then tested by teratoma 997 
differentiation assay. Data representative of n=3 three experiments (human PSC 998 
lines: H1, D2#2 and HERVH). (C) Immunofluorescence shows markers for 3 999 
embryonic germ layers in H1 and D2#2 cell lines (indicated). Scale bar 50µm. (D) 1000 
Summary of all tested lineage markers (6) determined by immunofluorecence in 1001 
teratomas generated from the three human PSC lines in (C). “+” = detected; “0“ = 1002 
not detected; “n/d” = not determined. Source Data Figure 3 summarizes all 1003 
differentiation markers tested for all three cell lines in (C,D). 1004 
(E) Interspecies chimera assay in vivo to assess developmental capacity of 1005 
human PSCs adapted to primed or CDK8/19i conditions. Constitutively-labelled 1006 
human PSCs (td:tomato-red; HERVH iPS cell line) were introduced into host 1007 
rabbit morulae of ~E2.5. Chimerism was assessed visually +72hrs later in ~E5.5 1008 
rabbit blastocyst. Below plot: indicated are the number of human cells introduced 1009 
(5 or 10), and number of embryos (n) in each of the three experiments (Exp1-3). 1010 
The bar chart quantifies the number of human cells observed in rabbit embryos; 1011 
data from 3 independent experiments.  A representative image shows 1012 
immunofluorescence of E.5.5 rabbit blastocyst, with inner cell mass indicated 1013 
(determined by Nanog staining, inset panel, below).  Human PSCs adapted to 1014 
CDK8/19i displayed moderate contribution to human-rabbit chimeras. Scale bar 1015 
20µm.  1016 
 
 
Figure 4:  1017 
 1018 
Gene expression in mouse and human PSCs adapted to 2i or CDK8/19i 1019 
 1020 
(A,B) Overlap and hypergeometric significance (A) of differentially expressed 1021 
mRNAs in mouse PSCs in 2i-naïve or CDK8/19i, versus serum/LIF (RNA-seq; 1022 
n=3 biological replicates; FDR<0.01). (B) Heatmap: changes in selected 1023 
pluripotency regulators.  1024 
(C,D) Overlap and hypergeometric significance of differentially expressed ERV 1025 
families (C), and overlap of 2-Cell (2C) fluctuation markers (D), in mouse PSCs in 1026 
2i-naïve or CDK8/19i, versus serum/LIF (n=3 biological replicates; FDR<0.05). 1027 
(E) Heatmap: normalized enrichment scores (NES) from GSEA comparison of 1028 
mouse RNA-seq data in (A) (n=3 biological replicates), or five other studies23,48–1029 
51, versus stage-specific marker genesets identified during mouse 1030 
preimplantation development52. Significant comparisons: P<0.05 and FDR 1031 
q<0.05, marked (*). 1032 
(F,G) Overlap and hypergeometric significance (F) of differentially expressed 1033 
mRNAs in human PSCs cultured as indicated versus control primed cells (RNA-1034 
seq; n=3 biological replicates, FDR<0.05, threshold >2x fold-change). (G) 1035 
Selected human naïve pluripotency markers (up), or post-implantation primed 1036 
epiblast markers (down) in human PSCs cultured as indicated. 1037 
(H,I) Heatmaps: correlation in RNA expression changes for ERV families (H; 1038 
n=1066 families, each row = Mean of family), or individual loci of selected ERV 1039 
families (I; genomic loci n=indicated) in human PSCs cultured as indicated 1040 
versus control primed cells. 1041 
(J) qRT-PCR: RNA expression in human PSCs cultured as indicated, as in (F) 1042 
(n=3 biological replicates, Mean+/-SD). 1043 
(K) Heatmap: NES scores from GSEA comparison of our human PSC RNA-seq 1044 
(n=3 biological replicates), or seven other studies (above heatmap)32–34,39,58–60, 1045 
verses stage-specific marker genesets identified during human preimplantation 1046 
development (below each heatmap)54–57. Lower panel: comparison, our data 1047 
 
 
versus other studies. Significant comparisons: P<0.05 and FDR q<0.05, marked 1048 
(*). 1049 
(L,M) Proteomic overview (L). Overlap and hypergeometric significance of 1050 
differentially expressed proteins averaged across five mouse PSC lines in 2i-1051 
naïve or CDK8/19i, versus standard serum/LIF culture (n=5 biological replicates, 1052 
FDR<0.05). Heatmap (M): protein changes in selected pluripotency regulators 1053 
per cell line. Data per cell line: Extended Data Fig.S5A,B. 1054 
Supplementary Table 2 and Source Data: full gene lists, ERV lists, fold 1055 
changes, statistical tests in (A-I, K). Supplementary Table 4 list of differentially 1056 
expressed proteins in (L,M). 1057 
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Figure 5:  1060 
 1061 
CDK8/19i regulates the phospho-proteome and RNA Pol II similar to 2i-1062 
naïve pluripotency, but not DNA methylation. 1063 
 1064 
(A) Global DNA methylation (5-methyl-cytosine) changes in n=4 mouse PSC 1065 
lines in 2i or CDK8/19i. Left panel, Mean of n=2 technical replicates for each cell 1066 
line. Right panel, Mean+/-SD of n=4 cell lines, t-test, unpaired, two-tailed, P-1067 
values indicated. 1068 
(B) Global DNA methylation (5-methyl-cytosine) changes in two human PSC 1069 
lines.  Mean+/-SD of n=2-6 biological replicates per cell line, as indicated. 1070 
(C) Pyrosequencing for CpG methylation status of three specific loci in LINE L1 1071 
family of repeat elements in mouse PSC in treatments indicated in n=1 mouse 1072 
PSC line (E14). 1073 
(D,E) Phosphoproteomic overview. Mouse ES lines in 2i or CDK8/19i for 15min. 1074 
(D) Pie-charts summarize total and differential phosphosites detected. (E) 1075 
Heatmap and Gene Ontology (GO) summary for proteins displaying significantly 1076 
differential phosphorylation. (D,E) n=2 biological replicates, FDR<0.05. 1077 
Supplementary Table 5: full protein lists. 1078 
(F,G) Western blots: protein phosphorylation during short-term exposure of PSCs 1079 
to 2i or CDK8/19i, as indicated. (F) Left: ERK1/2 phosphorylation in mouse 1080 
PSCs. Right: STAT1 Ser727 phosphorylation in human iPSCs. (G) Left: ERK1/2 1081 
phosphorylation in mouse ES cells. Right: plot shows relative ERK1/2 phospho-1082 
levels, normalized by total ERK1/2 levels. (F,G) Data representative of 2 1083 
biological experiements. 1084 
(H,I) ChIP-seq: RNA Pol II abundance at all Refseq Transcription Start Sites 1085 
(TSS; n=28,441), in mouse PSCs, treated as indicated. (H) Heatmap, TSS +/-1086 
5Kb. (I) Metagene average +/-2Kb. ChIP-seq n=3 pooled replicates. 1087 
(J) Cumulative plots of RNA Pol II loading ratios in mouse PSCs adapted to 1088 
culture conditions as in (H,I). RNA Pol II abundance was calculated in the 1089 
indicated regions (schematic) for each gene: promoter, gene body, and 1090 
transcription termination zone (Methods). The ratios of RNA Pol II abundance 1091 
 
 
between these regions were calculated for each gene, and displayed 1092 
cumulatively in the three plots (n=12,072 genes). For Promoter Loading Index 1093 
(PLI;  on left), dotted line indicates 90% of genes have PLI > 2.0. 1094 
Supplementary Table 6, and Source Data: full list of ChIP-seq data, genes, and 1095 
abundance ratios. 1096 
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Figure 6:  1099 
2i and CDK8/19i exert similar effects on Mediator, RNA Pol II loading, and 1100 
enhancer activity. 1101 
(A) Change in Total- or Ser5P-RNA Pol II abundance at TSS by ChIP-seq in 1102 
mouse PSCs in 2i or CDK8/19i versus serum/LIF control. Data: Mean+/-SD; 1103 
Total Pol II, n=12,693TSS; Ser5P, n=4,470TSS. 1104 
(B) Overlap and hypergeometric significance (P-value indicated) of genes where 1105 
RNA Pol II abundance at TSS increased >1.5xfold in 2i and CDK8/19i (as in A); 1106 
TSS n=12,072. 1107 
(C,D) Fold-change in RNA Pol II abundance at TSS (C), and fold-change in RNA 1108 
Pol II Promoter Loading Index (PLI) (D), on genes (n=12,693) where RNA Pol II 1109 
was detected in mouse PSCs in 2i or CDK8/19i versus control serum/LIF. 1110 
(E,F) Genes with largest changes in ChIP-seq RNA Pol II abundance correlate in 1111 
CDK8/19i or 2i-naïve conditions. (E), individual promoter-TSS with RNA Pol II 1112 
loading altered in CDK8/19i by greatest (upper panel) or least amount (middle 1113 
panel) versus serum/LIF control (top 200 TSS in each case), are compared 1114 
against a ranked list (bottom panel) of differential Pol II loading on all TSS for 2i-1115 
naïve versus serum/LIF control. (F) Reverse comparison: top 200 altered TSS in 1116 
2i-naïve versus ranked list of Pol II changes in CDK8/19i. 1117 
(G) CDK8/19 abundance in mouse PSCs, defined by ChIP-seq2,3, peak-calling, 1118 
and grouped by genomic localization. SE/TE: super/typical enhancers. Promoter-1119 
TSS: TSS+/-1Kb. Gene Body: Exons, Introns, Transcription Termination Site 1120 
TTS+/-1Kb. T-test, unpaired, two-tailed, ****P<0.001. 1121 
(H) RNA Pol II abundance in mouse PSC genomic regions without CDK8/19 1122 
binding (left, n=423), or with top 10% strongest CDK8/19 binding signals (right, 1123 
n=464), as defined: Extended Data Fig.8D. T-test, unpaired, two-tailed, Welchs 1124 
correction, ****P<0.0001. 1125 
(I) RNA Pol II abundance in mouse PSCs, at typical enhancers (TE; left, 1126 
n=9981), or super-enhancers (SE; right, n=646), as defined2,3. T-test, unpaired, 1127 
two-tailed, Welchs correction, ****P<0.0001. 1128 
 
 
(A-F,H,I): RNA Pol II abundance measured by ChIP-seq (3 pooled replicates). 1129 
(G,H,I): Tukey box plot centre lines show median values, box limits represent 1130 
upper and lower quartiles, whiskers show 1.5× interquartile range. Number of n 1131 
regions per group, P-value calculations, list of defined loci, and HOMER 1132 
functional annotations: Supplementary Tables 3,7; and Source Data. 1133 
  1134 
 
 
Figure 7:  1135 
2i and CDK8/19i hyperactivate naïve-state enhancer activity, conferring 1136 
resistance to enhancer destabilization. 1137 
(A) Left, qRT-PCR: pluripotency genes and naïve-specific enhancer RNA 1138 
(eRNA)71 abundance in mouse PSC at time intervals after exposure to 2i or 1139 
CDK8/19i, relative to standard serum/LIF control. Data: Mean+/-SEM, n=3 1140 
independent  experiments. Right: heatmap summarizing mean fold-change in 1141 
expression of the replicate experiments determined by qRT-PCR in left panel, 1142 
and Extended Data Fig.8G during inhibitor withdrawal. 1143 
(B,C) Selective up-regulation of SE-target genes. SE: super-enhancer. (B) Left: 1144 
GSEA of SE-target gene mRNAs in mouse PSCs adapted to CDK8/19i (n=3 1145 
biological replicates). SE-targets were defined as the single nearest gene by 1146 
GREAT analysis (Methods) and are significantly up-regulated (on left; 408 1147 
genes, FDR q-value<0.001). Right: expression-matched control genes (not 1148 
predicted to be enhancer targets, but which are highly expressed similar to SE-1149 
target genes) show no significant change in levels (right panel; 464 genes, FDR 1150 
q-value=1.0). (C) The relative specificity of SE-target gene up-regulation by 1151 
CDK8/19i was determined by comparison with databases of many other 1152 
genesets using GSEA. C5 Gene Ontology (GO) terms (n=3,844 genesets) and 1153 
C2 KEGG (n=150 genesets) as defined by the Broad Institute (Methods). SE-1154 
target genes lie within the top 1% most-significantly up-regulated genesets 1155 
realtive to these GO term or KEGG databases. (B,C) SE-target and expression-1156 
matched SE-non-target genes were defined as the single nearest gene by 1157 
GREAT analysis (Methods). Source Data for SE-target gene list (408 genes) 1158 
and expression-matched control geneset (464 genes). 1159 
(D) Brightfield images: typical cell morphology following treatment with 500nM 1160 
BRD4i/JQ1 for 48h (left) or 7d (right), in WT iPS cells or in CDK8/19-double-1161 
knockout (CDK8/19-dKO) iPS cells stably expressing pMSCV-CDK8-Kinase 1162 
Dead (CDK8-KD). Panels on right show brightfield image of colonies which have 1163 
been fixed and stained for alkaline phosphatase at Day 21/passage 5 of 1164 




(E) qRT-PCR expression of naïve-specific eRNA71 and marker genes following 1167 
treatment with 500nM BRD4i/JQ1 for 48h. CDK8/19-dKO iPS +/- CDK8-KD were 1168 
cultured +/- 2i or standard serum/LIF, as indicated. Mean+/-SD, n=3 clones. 1169 
  1170 
 
 
Figure 8: 1171 
CDK8 expression in vivo and role of Mediator during mouse 1172 
preimplantation development 1173 
(A,B) Immunofluorescence and quantification of CDK8 expression at indicated 1174 
timepoints during early mouse embryo development. (A) Single Z-section shown. 1175 
(B) CDK8 protein levels per nucleus quantified per timepoint relative to internal 1176 
controls. OCT4/GATA6 co-expression marks all ICM cells at E3.5. OCT4/GATA6 1177 
segregation from E4.5 to E5.5, marks epiblast (Epi/OCT4+) and primitive 1178 
endoderm (PE/GATA6+), which later forms visceral endoderm (VE) at E5.5. 1179 
Embryo staging, CDK8 quantification and normalization (Methods). Data: 2 1180 
independent experiments (images representative), ICM, 6 embryos, n=64 nuclei; 1181 
E4.5, 5 embryos, nuclei: n=51(Epi), 48(PE); E5.0, 5 embryos, nuclei: n=48(Epi), 1182 
n=52(PE); E5.5, 6 embryos, nuclei: n=100(Epi), n=84(PE/VE) (see: Source 1183 
Data). Plot: Mean+/-SD; significance assessed by Kruskal-Wallis test with Dunn’s 1184 
multiple comparisons. 1185 
(C,D) CDK8 expression is repressed by MEK-inhibition in vivo. Embryos were 1186 
incubated 48h +/- MEKi (E3.5 morula to E4.5 blastocyst). (C) 1187 
Immunofluorescence: CDK8 protein expression in E4.5 blastocyst. Data 1188 
representative of 3 experiments. (D) CDK8 protein levels per cell quantified in 1189 
ICM, or Trophectoderm, relative to internal controls, per z-slice/image. Left: 1190 
Control, n=7 embryos, 55 images; MEKi, n=12 embryos, 44 images. Right: 1191 
Control, n=22 embryos, 22 images; MEKi, n=27 embryos, 27 images. Tukey box 1192 
plot centre lines show median values, box limits represent upper and lower 1193 
quartiles, whiskers show 1.5× interquartile range; significance assessed by T-1194 
test, unpaired, two-tailed, ***P<0.001; ns = not significant. 1195 
(E-G) CDK8/19-inhibition does not prevent Epi/PE segregation. E3.5 embryos 1196 
were incubated 24h +/- CDK8/19i, during Epi/PE segregation, then assessed by 1197 
immunofluorescence (images representative; E,G). (F) bar charts: quantification 1198 
of ICM cell number, and lineage allocation in ICM, defined as: Epi/NANOG+; 1199 
PE/GATA6+; ICM: Nanog+ or Gata6+). Data: Mean+/-SEM; 2 experiments; 1200 
significance by T-test, unpaired, two-tailed; ns not-significant; number of 1201 
embryos: control: n=7; CDK8/19i: n=9. 1202 
 
 
(H) CDK8/19-inhibition interrupts pre- to post-implantation morphogenic events. 1203 
Pre-implantation E4.5 embryos were cultured until E5.0 in vitro35 +/- CDK8/19i. 1204 
PODXL/F-ACTIN staining determines emergence of epiblast pro-amniotic 1205 
cavity/lumen (outlined in representative images). Right: Morphogenesis 1206 
quantified; significance by Chi-square test, *P<0.05. Data: 2 experiments; 1207 
number of embryos: Control, n=15; CDK8/19i, n=16. 1208 







For primers, antibodies, shRNAs, and CRISPR-Cas9 gRNAs: Supplementary Table 8 3 
 4 
 5 
PLURIPOTENCY AND DIFFERENTIATION ASSAYS 6 
 7 
Mouse and human work 8 
Animal experimentation at the Spanish National Cancer Research Centre CNIO (Centro 9 
Nacional de Investigaciones Oncológicas) performed according to protocols approved 10 
by CNIO-ISCIII Ethics Committee for Research and Animal Welfare (CEIyBA). 11 
Animal experimentation at University of Cambridge was approved by the Home Office, 12 
performed according to Animals (Scientific Procedures) Act 1986 Amendment 13 
Regulations 2012, and reviewed by University of Cambridge Animal Welfare and 14 
Ethical Review Body (AWERB). Cdk8-flox/flox RERT-Cre mice were generated by 15 
Daniel Fisher (IGMM, Montpellier). 16 
Human pluripotent stem cell studies were ethically approved in CNIO, Madrid, by the 17 
Comisión de Garantías para la Donación y Utilización de Células y Tejidos Humanos, 18 
and signed by Director of Instituto de Salud Carlos III (Nuevas fronteras en la 19 
Reprogramación Celular: Explotando la plasticidad cellular; Ref: 303). Studies at the 20 
IRB Barcelona, were approved by Ethics Committee of CMRB, and by Comisión de 21 
Seguimiento y Control de la Donación de Células y Tejidos Humanos del Instituto de 22 
Salud Carlos III and Ministry of Health from Government of Catalonia (project 23 
numbers: 0336S/11730/2015; 0336S/11220/2016; 0336S/2473/2017; 0336/747/2018). 24 
 25 
Mouse cells and culture conditions 26 
Mouse Pluripotent Stem Cells (PSCs): E14Tg2a.4 (wild-type parental, 129/Ola 27 
background) from BayGenomics/MMRRC resource, University of California; Wild-28 
type PSCs were derived at the Transgenic Mouse Unit of CNIO from E3.5 C57BL6 29 
blastocysts, or mixed background C57BL6/129 blastocysts; Rosa26-GFP and Tg.CAG-30 
Katushka-red PSC lines were derived from 129-Gt(ROSA)26Sortm1(CAG-EGFP)Luo/J mice 31 
(Jackson 006053) and from Tg.CAG-Katushka mice81, respectively. Nanog-GFP knock-32 
in mouse PSCs (TNGA, TON) as described29 and shared by laboratory of Austin Smith. 33 
MERVL-td:Tomato mouse 2C-reporter PSCs were shared by laboratory of Todd 34 
Macfarlan46. ZS mouse 2C-reporter PSCs were shared by laboratory of Minoru Ko82.  35 
Mouse PSCs (ES cells and iPS cells), were routinely cultured on 0.1% gelatin-coated 36 
plates in a base media of either “Serum/LIF” (15% FBS), or Knockout Serum 37 
Replacement (KSR, Invitrogen) “KSR/LIF” (15% KSR), in DMEM (high glucose) 38 
basal media, with LIF (1000 Units/mL), non-essential amino acids, glutamax and β-39 
mercaptoethanol plus antibiotics.  Where used with mouse PSC, the “2i” two-inhibitor 40 
cocktail comprised 1µM MEK-inhibitor (PD0325901, Axon Medchem, #1408) plus 41 
3µΜ GSK3β-inhibitor (CHIR 99021, Axon Medchem #1386) as described25. Cultures 42 
were routinely tested for mycoplasma. Primary mouse embryo fibroblasts (wild-type, 43 
MEFs, passage 2) were obtained at E13.5 from pure inbred C57BL6 background mice, 44 
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or from CDK8-flox/flox RERT-Cre mice. Human 293T cells were from ATCC. All 45 
above-mentioned cells were maintained in: DMEM, 10% FBS (Gibco), with antibiotics 46 
(penicillin/streptomycin 100U/ml). Reprogrammed iPS cells were initially derived and 47 
expanded on mitomycin-C inactivated feeder cells on gelatin-coated plates, before 48 
transfer to gelatin-only. 49 
 50 
Human PSC cell resources 51 
HERVH iPS PSCs were shared by laboratory of Zsussanna Izsvak (Max Delbruck 52 
Centre for Molecular Medicine)37. WIBR3 ES PSCs were shared by laboratory of Jacob 53 
Hanna (Weizmann Institute of Science). OSCAR ES PSCs carrying inducible STAT3 54 
were shared by laboratory of Pierre Savatier (SBRI, Stem Cell and Brian Research 55 
Institute)36.  H1 and H9 human ES PSCs, and CB5, D2#2, and D2#4 human iPS PSCs, 56 
were shared by laboratory of Nuria Montserrat (IBEC, Institute for Bioengineering). 57 
 58 
Human PSC cell culture in primed state 59 
Human PSC (H1, H9, WIBR3, HERVH, CB5, D2#2, D2#4, OSCAR) were maintained 60 
in conventional primed conditions as described33,36,37, specifically, by culture on growth 61 
factor-reduced phenol red-free matrigel (BD Biosciences #356231) with mTeSR1 media 62 
(Stem Cell Technologies). Cultures were passage every 5-7 days manually using either 63 
2mg/ml dispase (Gibco), 0,5µM  EDTA/1xPBS, or accutase (Gibco). 64 
 65 
Resetting human PSC from primed to naïve state using 2i-based media cocktail  66 
The naïve human pluripotent state was obtained by two methods. OSCAR PSCs were 67 
reset to the naïve state with 2i (TL2i) or CDK8/19i (1,1µM or 0,4µM) plus rhLIF and 68 
STAT3 transgene induction, as described36.  In a transgene-free approach, human PSCs 69 
were cultured in a 2i-based chemical cocktail33 referred to here as “2i p38iJNKi”. Cells 70 
were maintained on matrigel (BD Biosciences #356231) using mTeSR1 (Stem Cell 71 
Technologies). Media was supplemented with 20ng/ml of recombinant human LIF 72 
(Peprotech, as described33, 1µM PD0325901 (MEKi, Axon Medchem), 1.5µM CHIR 73 
99021 (GSK3i, Axon Medchem), 10µM SP600125 (JNKi, TOCRIS) plus 2µM 74 
BIRB796 (p38i, Axon Medchem). In order to obtain and maintain the naïve state using 75 
the 2i p38iJNKi media cocktail, cells were selected at each passage, by cytometry 76 
sorting for the top 10% HERVH-GFP levels, or by repeated manual picking for 77 
selection of colonies with dome-shaped morphology.  Conversion of human PSC from 78 
primed to naïve required 3 passages/rounds of selection, over 14-18 days. 79 
 80 
Resetting human PSC from primed to naïve pluripotent state using CDK8/19i  81 
To adapt and maintain human PSC to CDK8/19i culture (CDK8/19i-adapted), cells 82 
were maintained on matrigel (BD Biosciences #356231) using mTeSR1 (Stem Cell 83 
Technologies). Media was supplemented with 20ng/ml of recombinant human LIF 84 
(Peprotech), as described33, plus 0,4µM or 1.1µM of CNIO-CDK8/19 inhibitor, or plus 85 
10µM of SenexinA-CDK8/19 inhibitor83. This adaption process was also successful 86 
with 10µM SP600125 (JNKi, TOCRIS) plus 2µM BIRB796 (p38i, Axon Medchem), 87 
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but these additives are not required with CDK8/19i. Following background cell death in 88 
the first passage, colonies gradually become dome-shaped within 10-14 days without 89 
additional selection, and could be expanded by passage, using 3–5min treatment with 90 
Accutase (Gibco) or 0,5µM  EDTA/1xPBS to avoid confluency, usually every 5-7 days 91 
due to a slowdown in proliferation. The optimal CDK8/19i concentration was 1.1µM 92 
for HERVH-GFP human iPSC, while it was 0,4µM for all other human PSC lines. 93 
 94 
Mouse ESC derivation 95 
ES cell line derivation was by standard methods. 8-cell stage mouse embryos from 96 
oviducts of pregnant females were cultured in serum/LIF on mitomycin C-inactivated 97 
MEF feeders plus 2i or CDK8/19i (added fresh every 2 days) until emergence of 98 
colonies from hatched blastocysts. Feeders were not compatible with several days of 99 
CDK8/19i, therefore cells were passed every 2 days to fresh feeders, then transferred to 100 
0,1% gelatin-only.  101 
 102 
Mouse EpiSC derivation 103 
PSCs in 2i/LIF cultured on gelatin were firstly induced to differentiate into Epiblast-104 
Like Cells (EpiLCs) over 48h by seeding on fibronectin-coated plates (10ng/ml) and 105 
switching to media containing 1%KSR, N2B27, FGF2 (12ng/ml) and Activin A 106 
(20ng/ml)50. After 48h, the cells were in a flat EpiLC state, and media was switched to 107 
include 20% KSR, and expanded for 5 passages to stabilize the EpiSC primed state, 108 
confirmed by typical flat colony morphology and Fgf5 expression. EpiSC colonies were 109 
passaged as clumps. 110 
 111 
Analysis of PSC self-renewal 112 
Mouse or human PSC self-renewal and pluripotency was scored by colony morphology, 113 
cytometry (mouse: Nanog-GFP heterogeneity and overall intensity, and co-staining for 114 
ICAM1; human: HERVH-GFP intensity, and assessing expression of NANOG, OCT4, 115 
SSEA4, TRA1-81), by alkaline phosphatase staining (fixed cells; Promega #S3771), 116 
and by immunofluorescence and qRT-PCR (for pluripotency markers, indicated in each 117 
Figure). Alkaline phosphatase staining intensity was quantified by scoring colonies 118 
observed by brightfield microscopy in 10 random fields of view per well. 119 
 120 
Mouse PSC differentiation with LIF-removal and retinoic acid  121 
LIF was first removed for 24h by culture in LIF-free Differentiation medium (as for 122 
serum/LIF media except the LIF is omitted). Next, Retinoic Acid was added at 10µM 123 
from +24 to +72h, followed by LIF-free differentiation medium alone from +72 to 124 
+96h. Differentiation was also assessed by the same protocol of LIF-withdrawal except 125 
without adding Retinoic Acid. 126 
 127 
Mouse PSC differentiation by hanging-drop and embryoid bodies 128 
PSCs were transferred to LIF-free Differentiation medium (as above) and suspended in 129 
hanging drop culture at 1000-5000 cells/20µLs for 48h to form Embryoid Bodies (EBs), 130 
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followed by transfer to suspension culture in low-adherence petri-dishes. Fresh medium 131 
was added every 3d, and development of beating cells in cardiac centres was scored 132 
daily. 133 
 134 
Mouse chimera assays : morula aggregation and blastocyst micro-injection 135 
Following 10 passages in serum/LIF, 2i, or CDK8/19i, mouse PSCs labelled 136 
constitutively with Rosa26-GFP or Tg.CAG-Katushka81 underwent morula aggregation 137 
at E2.5, or blastocyst micro-injection at E3.5, as described25. The extent of GFP+ or 138 
Katushka-red+ cell chimeric contribution was assessed by confocal fluorescence at 139 
E4.5, or embryos were introduced into CD1 pseudo-pregnant females for implantation, 140 
and harvested at post-implantation time-points: E6.5, E14.5, or E19.5. Chimeras 141 
developed to adulthood were assessed by coat colour contribution and capacity for 142 
germline transmission. 143 
 144 
Cardiac and endoderm directed differentiation of EBs derived from hPSCs. 145 
Human PSC colonies were dissociated and cultured in suspension for 3d to form EBs in 146 
DMEM/F12, 15% FBS, 2 mM L-glutamine, non-essential amino acids, and 147 
penicillin/streptomycin. To generate endoderm, EBs were transferred to 0.1% gelatin-148 
coated plates for 2 weeks in differentiation medium (DMEM, 20% FBS, 2mM L-149 
glutamine, 0.1mM 2-mercaptoethanol, non-essential amino acids, and penicillin-150 
streptomycin). To generate cardiac tissue, differentiation medium was supplemented 151 
with 100μM ascorbic acid (Sigma). In all conditions, EBs spontaneously gave rise to 152 
neural cell clusters. 153 
 154 
Teratoma assays 155 
Mouse PSCs: 106 cells in 100µl were injected sub-cutaneously in nude mice. Human 156 
PSCs: 2x106 cells in 30µl were injected into testis of male SCID beige mice. 157 
 158 
Mouse embryo manipulation and analysis 159 
Mouse embryo collection, culture for pre-implantation embryo development in vitro, 160 
and fixation for immunofluorescence, as described74. Pre- to post-implantation embryo 161 
development in vitro, immunofluorescence analysis of CDK8 and Cyclin C levels in 162 
pre-implantation mouse embryos, and lumenogenesis by mouse PSC embryoid 163 
formation in Matrigel, as described35; further details on request. 164 
 165 
Viral production and iPS (induced pluripotent stem) cell reprogramming 166 
As described84. Briefly, retroviral and lentiviral supernatants were produced in HEK-167 
293T cells. Filtered supernatants were collected after 48h, and added to recipient cells in 168 
4 infections. Retroviral supernatants delivered exogenous CDK8 expression constructs 169 
and iPS reprogramming vectors. Lentivirus supernatants delivered shRNA knockdown 170 
vectors and CRISPR-Cas9 vectors. Plasmids: Supplementary Table 8. 171 
 172 
Interspecies chimera developmental potency 173 
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Primed human iPS PSCs were pre-cultured with ROCK-inhibitor 24h, prepared as a 174 
unicellular suspension, and electroporated (Neon Transfection System; Invitrogen; 1-175 
pulse/1400V/20ms) with 10µg of DNA constructs for constitutive tdTomato expression 176 
(PB-Hygro-PGK-CAG-tdTomato and PBase pCMV-Transposase). Cells were 177 
subsequently plated on matrigel in mTeSR1 medium supplemented with ROCK 178 
inhibitor for 24h, then antibiotic selection with 20µg/ml hygromycin was applied for 179 
12d, before cytometric sorting for tdTomato constitutively-labelled cells. 180 
 181 
Sexually mature NZW female rabbits (HyPharm ; Roussay, France) were super-182 
ovulated. 60h after artificial insemination. Fertilized embryos (8-cell stage ; E1.5) were 183 
flushed from explanted oviducts by using Euroflush® (IMV Technologies) and cultured 184 
in RDH medium (1/3 volume of DMEM-GlutaMAX, 1/3 volume of RPMI-GlutaMAX, 185 
and 1/3 volume of Ham's F10-GlutaMAX; Life Technologies) at 38°C, 5% CO2. 186 
 187 
Human PSCs were dissociated into single-cell suspension with trypsin, and 5–10 cells 188 
were micro-injected under the mucus coat and zona pellucida of morula 8-cell stage 189 
rabbit embryos, the day after collection. After microinjection, embryos were 190 
sequentially cultured in CDK8/19i media for 4h, followed by 20h incubation with 1:1 191 
mixture of RDH:CDK8i media and finally in RDH medium for extended in vitro 192 
culturing. After 24h of in vitro culture, early blastocyst stage embryos (E3.5) were 193 
rinsed x3 in embryo-holding medium (IMV Technologies) and treated with 5mg/ml 194 
protease E (Sigma), 3min at 37°C, to digest mucus coat and weaken zona pellucida. 195 
Embryos were then rinsed x3 in 199 HEPES medium (Sigma) and cultured in RDH 196 
medium for 3d until late-blastocyst stage (E5.5). Rabbit embryos were fixed in 2% para-197 
formaldehyde for 20min at room temperature, washed in PBS + 0.1% Tween-20, and 198 
permeabilized in PBS + 1% Tween-20 overnight at 4°C. After 1h blocking with 5% 199 
donkey serum, embryo immunofluorescence was as described36. Antibodies:  200 
Supplementary Table 8. 201 
 202 
 203 
MOLECULAR METHODS 204 
 205 
Transcriptional CDK inhibitors 206 
Structure and characterization of the CNIO CDK8/19 inhibitor (CDK8/19i-47799), and 207 
notes on all other transcriptional CDK inhibitors used in this study, see: 208 
Supplementary Table 1. 209 
 210 
Small molecule inhibitor characterization assays 211 
In vitro enzyme-inhibitor quantitative assays with recombinant proteins were performed 212 
using LanthaScreen ™ Eu-Kinase Binding Assay (Invitrogen) for: CDK8/Cyclin C, 213 
CDK9/CyclinT; CDKs, DYRK1A, GSK3β, mTOR, PI3K, PIM1/2, FLT3, KDR, KIT, 214 
PDGR-α and SRC. Data from small molecule inhibitor characterization assays are 215 




Generation of CDK8/19-double knockout iPS cells 218 
To target mouse CDK19, we designed sgRNA against CDK19 exon1, targeting 76bp 219 
downstream of the ATG start of translation to generate indels (schematic: Extended 220 
Data Fig.1I). Supplementary Table 8, for sgRNA sequences, and plasmid details. 221 
Primary CDK8-flox/flox RERT-Cre MEFs of passage P+1 to P+4 were infected with 222 
lenti-CRISPR-Cas9 containing the CDK19 sgRNA (pLenti-CRISPRV2; Addgene 223 
#52961) followed by selection with puromycin (1µg/ml). CDK19-knockout was 224 
assessed by Western blot. The MEFs were reprogrammed to iPS, where single clones 225 
were picked, expanded and CRISPR-induced indels characterized by sequencing the 226 
CDK19 target region for frameshift mutations. CDK19-knockout iPS clones were 227 
compared versus iPS clones which retained wild-type CDK19 expression, and no effect 228 
of CDK19-knockout was observed in MEFs or in iPS cells. CDK8-knockout was 229 
induced by 6d culture with 0.5µM 4-hydroxy-tamoxifen to induce Cre-mediated 230 
deletion of CDK8 exon2 (schematic: Extended Data Fig.1J). CDK8-knockout was 231 
confirmed by allele-specific PCR (to demonstrate exon 2 deletion; Extended Data 232 
Fig.1H), and by western blot (to demonstrate complete loss of CDK8 protein; 233 
Extended Data Fig.1J,K). 234 
 235 
Stable exogenous expression of CDK8 236 
Wild-type CDK8 (CDK8-WT) and catalytically-inactivated kinase-dead CDK8 (CDK8-237 
KD; D173A) were cloned into pMSCV-puro-IRES-GFP (Addgene #21654) using BglII 238 
and HpaI restriction enzymes, and confirmed by sequencing. Retroviral supernatants 239 
were generated in 293T cells with packaging plasmid pCl-Eco (Addgene#12371), 240 
followed by retroviral expression into CDK8/19-double knockout iPS cells. Two rounds 241 
of FACS-selection by GFP expression were used to enrich for expressing cells, and 242 
CDK8-WT or CDK8-KD protein expression was confirmed by Western blot (schematic 243 
and Western blot data in Fig.1K and Extended Data Fig.1L). 244 
 245 
FACS Cytometry 246 
FACS  for SSEA1 or ICAM1 was performed with FlowJo 9.6.2 software as described84. 247 
Live cell analysis of the Nanog-GFP used 2i-adapted mouse PSCs to define the  248 
threshold (95% of cells) for the homogenous Nanog-GFPhigh population, against which 249 
other treatment were compared (Fig.1A,B). Live cell sorting for human PSC carrying 250 
HERVH-GFP selected the top 10% GFP-expressing cells, as previously described37. 251 
Extended Data Figure 9G: FACS gating strategy for live/dead cell discrimination. 252 
 253 
Cell lysis, fractionation, and Western blot 254 
As described84. Antibodies: Supplementary Table 8. Nuclear/Cytoplasmic 255 
fractionation: using NE-PER kit (Thermofisher #78833). 256 
 257 
G-banding Karyotype methodology 258 
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Subconfluent mouse and human PSC lines were arrested at metaphase stage by adding 259 
0,02µg/ml KaryoMax colcemid (Gibco). 20 metaphase spreads were analysed per 260 
condition. 261 
 262 
Mouse embryo immunohistochemistry and immunofluorescence 263 
Mouse tissues were fixed in formalin at 4ºC, embedded in paraffin block, and sectioned 264 
at 5µm thickness. Staining by standard methods. Antibodies: Supplementary Table 8. 265 
 266 
Mouse teratoma and embryoid body immunohistochemistry 267 
As described84. Antibodies : Supplementary Table 8. 268 
 269 
Cell immunofluorescence 270 
PSCs were grown on chamber slides using culture conditions indicated in each 271 
experiment. Confocal immunofluorescence staining and microscopy, as described35,84 272 
using Leica SP5 microscope. Antibodies: Supplementary Table 8.  273 
 274 
DNA methylation 275 
Global DNA methylation status was quantified by mass spectrometry. CpG methylation 276 
status at individual CpG sites of repeat DNA regions assessed by DNA bisulphite-277 
conversion and pyrosequencing. Primers for PCR amplification and sequencing: 278 
Supplementary Table 8. 279 
 280 
Image analysis 281 





Full proteome quantitative analysis of 5 mouse ES cell lines  287 
Five mouse ES cell lines (ZS, TNGA, TON, BL6 and V6.4) were cultured in serum/LIF 288 
(as control), or additionally, with either 2i or CDK8/19i for >2 weeks. Cell pellets were 289 
collected by trypsinization, washed with cold 1xPBS and preserved immediately at -290 
80ºC for further analysis. Protein sample preparation for mass spectrometry, protein 291 
digestion, our scheme for isobaric labelling with iTRAQ8plex, detailed settings for high 292 
pH reverse phase fractionation, detailed settings for the whole proteome LC-MS/MS, 293 
and bioinformatic analyses with the whole Proteome data, as described84. 294 
 295 
Phospho-proteome analysis of mouse PSC lines after 15 min of inhibitor treatment 296 
Two mouse ES PSC lines (TON and ZS) were cultured in serum/LIF (as control), or 297 
additionally, with either 2i or CDK8/19i.  Inhibitor treatment of the cells was precisely 298 
15min, after which, cells were collected rapidly by scraping in ice-cold PBS, washed 299 
with ice-cold PBS, snap-frozen on dry ice, and preserved at -80ºC for further analysis. 300 
Sample preparation for mass spectrometry, protein digestion, isobaric labelling, 301 
phosphopeptide enrichment, micro high pH reverse phase fractionation, settings used 302 
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for phospho-proteome LC-MS/MS, and bioinformatic analyses with phospho-proteomic 303 





RNA isolation and Quantitative real-time PCR (qRT-PCR) 309 
Total RNA was extracted (on-column; RNeasy kit with DNA digestion; Qiagen #74104, 310 
#79254), and retro-transcribed into cDNA (Superscript Reverse Transcriptase; Biorad 311 
#170-889). Quantitative real time-PCR (qRT-PCR) was performed using GoTaq qPCR 312 
Master Mix (Promega A6002) in an ABI PRISM 7700 thermocycler (Applied 313 
Biosystem). Input normalization of all qRT-PCR data was by the 2-∆∆Ct method using 314 
housekeeping genes β-Actin or Gapdh as indicated in each Figure. Primer list: 315 
Supplementary Table 8. 316 
 317 
RNA-seq transcriptomic analyses 318 
The complete set of reads has been deposited in GEO (GSE112208 and GSE127186). 319 
Complete list of meta-analyses expression comparisons between this study and multiple 320 
mouse and human published datasets, in vitro and in vivo, see: Source Data related to 321 
each Figure panel. 322 
 323 
For RNA-seq in mouse, samples of 1μg of total RNA (RIN numbers: 9.8-10; Agilent 324 
2100 Bioanalyzer), were used. PolyA+ fractions were processed using TruSeq Stranded 325 
mRNA Sample Preparation Kit (Agilent). Adapter-ligated library was completed by 326 
PCR with Illumina PE primers (8 cycles) and sequenced for 40 bases in a single-read 327 
format (Genome Analyzer IIx, Illumina). 328 
For RNA-seq in human, samples of total RNA (RIN numbers: 9.0-10; Agilent 2100 329 
Bioanalyzer), were used. For library construction 10ng of total RNA samples were 330 
processed with SMART-Seq v4 Ultra Low Input RNA Kit (Clontech) by following 331 
manufacturer instructions. Resulting cDNA was processed with the NEBNext Ultra II 332 
DNA Library Prep Kit for Illumina (NEB #E7645). Adapter-ligated libraries were 333 
completed by PCR (8 cycles), and sequenced for 50 bases in a single-read format, 334 
(Illumina HiSeq2500). 335 
Reads were aligned to the reference mouse genome (GRCm38/mm10) or the human 336 
genome (GRCh37/hg19) with TopHat-2.0.4 (using Bowtie 0.12.7 and Samtools 0.1.16, 337 
allowing two mismatches and five multi-hits. Transcripts assembly, estimation of 338 
abundance, and differential expression, were calculated with Cufflinks 1.3.0. When 339 
comparing samples, total read numbers were normalized, and visualized using 340 
SeqMiner 1.3.3e or IGV (Integrated Genome Viewer) from the Broad Institute available 341 
at: http://software.broadinstitute.org/software/igv/ 342 
 343 
Functional analyses of differential gene expression 344 
For differential gene expression lists, see: Supplementary Table 2 for mouse PSCs 345 
adapted to control serum/LIF, +2i, or +CDK8/19i: see, Supplementary Table 3 for 346 
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human PSCs adapted to control/primed, +2i, or +CDK8/19i. Genes were ranked using 347 
the FDR q-value statistic to identify significant genes (FDR<0.05), then by fold change 348 
in expression. Venn diagrams and hypergeometric testing were performed to assess any 349 
significant overlaps. Gene Set Enrichment Analysis (GSEA_Pre-ranked) was performed 350 
with MsigDB Hallmarks, C5-Gene Ontology (GO) terms, C2-Curated, KEGG, 351 
Reactome and NCI databases, with standard settings, and with 1000 permutations for 352 
Kolmogorov-Smirnoff correction for multiple testing. GSEA enrichment data were 353 
obtained and ranked according to FDR q-value (significance threshold: FDR q-value 354 
<0.25). Heatmaps of expression data were generated using Gene Pattern. RRHO (Rank 355 
Rank Hypergeometric Overlap) was performed using the ranked list of Log2_fold-356 
change in gene expression, or RNA Pol II abundance, using standard settings85. Colour 357 
intensity of RRHO heatmap indicates the -log10 p-value after Benjamini-Yekutieli 358 
correction of the hypergeometric overlap 359 
(http://systems.crump.ucla.edu/rankrank/rankranksimple.php)85. 360 
Analysis of Repeat sequences and Endogenous Retrovirus (ERV) expression was by 361 
using Repbase datasets for rodent or human repeat elements and featureCounts. In 362 
Extended Data Fig.3H, the total FPKM for RNA expression of LINE L1 sub-types was 363 
calculated by grouping and summing by family, and then arranged by evolutionary 364 
age86. Full list of 3 biological replicates for each viral sub-type and calculation for 365 
summary into each viral LINE L1 family: Supplementary Table 2, and Source Data. 366 
 367 
Differential gene expression comparing published mouse/human studies 368 
Gene expression changes have been comprehensively characterized in mouse, primate, 369 
and human PSCs in response to over-expression of transcription factors, upon culture in 370 
various media cocktails, or in vivo, during development of the mouse or human 371 
embryos87,88 (see full list of datasets and references used here: Supplementary Tables 372 
2 and 3; Source Data). We used the marker genesets for each developmental stage, to 373 
perform GSEA on the ranked list of genes up/down in the cellular studies of mouse and 374 
human. We also performed the analysis in reverse, comparing the genesets of 375 
significantly differentially expressed mRNAs up- or down-regulated in our cells, versus, 376 
the complete ranked list of differential gene expression in other studies. GSEA results 377 
are shown in Fig.4E (mouse) and Fig.4K (human). The readout is the Normalized 378 
Enrichment score (NES). Data with P<0.05 and FDR q<0.05 are considered significant 379 
and marked with an asterisk (*) in heatmaps of GSEA NES scores. 380 
          381 
 382 
CHIP-SEQ AND GENOMIC ANALYSES 383 
 384 
ChIP Methods and analyses 385 
ChIP-qPCR was performed as described84 with primers and antibodies listed in 386 
Supplementary Table 8. ChIP-seq, performed as described2,3,68,84. We performed 6 387 
biological replicates for each condition (3: serum/LIF, 2i, CDK8/19i) and for each 388 
antibody (3: total RNA Pol II, Ser5P-RNA Pol II, control IgG). Three replicates were 389 
used for ChIP-qPCR validations, and the other three replicates were pooled for 390 
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sequencing. We note that our RNA Pol II ChIP-seq data for serum/LIF and 2i-naïve 391 
cells very closely match ChIP-seq involving the same comparison, that is, mouse PSCs 392 
in primed versus 2i-naïve states23,69: compare Fig5H,I versus Extended Data Fig.6C. 393 
Definition of promoter and gene body regions and calculation of RNA Pol II total and 394 
Ser5P abundance along genes was based on methods of Young and colleagues68,84 (see 395 
schematic: Figure 5; Pol II abundance data: Supplementary Table 6; Source Data 396 
Figure 5). RNA Pol II abundance was assessed by normalizing the total number of 397 
reads between treatments, and using featureCounts to calculate the background-398 
subtracted Log2_RPKM of RNA Pol II abundance in the indicated regions. 399 
Transcription Start Site (TSS) and Transcription Termination Zone (TTZ) were 400 
identified using Database of Transcriptional Start Sites (http://dbtss.hgc.jp). Metagenes 401 
were aligned +/-5Kb or +/-2Kb around the TSS, and visualized by SeqMiner. 402 
 403 
The promoter, gene body and transcription termination zone (TTZ), and the ratios 404 
between these three regions for each gene (see schematic in Fig.5J and Extended Data 405 
Fig.6D, Supplementary Table 6), were defined similar to previous descriptions68,84. 406 
Total and Ser5P RNA Pol II abundance were quantified at promoter, gene body and 407 
TTZ for 31,167 Refseq gene loci where the transcription start and stop sites are known 408 
(Supplementary Table 6) in four steps, similar to previous reports68: (i) the number of 409 
reads per nucleotide was computed with BEDTools 'genomecov'; (ii), to extend this 410 
number to the number of reads per gene promoter or gene body, BEDTools 'map' was 411 
used; (iii), to correct for region size, the RNA Pol II abundance was calculated as: 412 
((number of reads in region / region size)*scaling factor)*105, where scaling factor = 413 
(total number of reads in sample/genome length); (iv), for the analysis of Pol II 414 
abundance according to inhibitor treatment, genes were first filtered for high confidence 415 
Pol II detected at threshold of >3,000 units at the promoter, and detected in all three 416 
conditions (serum/LIF, 2i or CDK8/19i), yielding 12,072 genes (Supplementary Table 417 
6 and Source Data, for filtering and calculations). In Fig.5H, and Extended Data 418 
6A,C, genes were arranged in rank by the abundance of RNA Pol II in the promoter 419 
region in the control serum/LIF condition. 420 
 421 
CDK8/19 enrichment across the genome of wild-type mixed background V6.5 422 
(C57BL/6-129) mouse PSCs was determined using published dataset: GSE44286, 423 
GSM1082346, as previously described2,3, with peak calling by MACS v1.4.1 using 424 
standard settings and compared to input negative control. Note, the ChIP antibody for 425 
this ChIP-seq (Santa Cruz #sc-1521) is reported to bind to both CDK8 and CDK1989. 426 
Peak annotation within local genomic features, was done using HOMER and the 427 
enhancer regions previously defined as constituent regions of typical enhancers 428 
(n=9,981) or super-enhancers (n=646)2,3, and of super-enhancer extended regions 429 
(n=231) as defined2,3, where enhancers were defined by co-enrichment for Oct4, Sox2, 430 
Nanog, and Med1. For peak calls, CDK8/19 abundance at called peaks, and loci 431 
annotations, see: Supplementary Table 7 and Source Data. Naïve-specific or primed-432 
specific enhancer regions were defined by filtering the PREStige database of 433 
enhancers77 which identifies enhancers by enrichment of H3K4me1 mono-methylation 434 
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in multiple tissues and lineages. Using the PREStige dataset, we identified enhancer 435 
regions with H3K4me1 enrichment >20 units, and specific only to pre-implantation 436 
naïve PSCs, or post-implantation EpiSC cells, versus all other tissue-specific enhancer 437 
regions listed in the database (~120,000), by subtraction of overlapping enhancers (1bp 438 
overhang threshold) as outlined in the schematic of Extended Data Fig.8E; see Source 439 
Data: for naïve ES-specific enhancers (n=1,424), or EpiSC-specific enhancers 440 
(n=1,005) lists. To identify the single-nearest target gene to each PSC super-enhancer 441 
and analyze their biological functions, GREAT v3.0.090 analysis was performed with 442 
standard settings, using the list of CDK8/19 peaks identified above (Supplementary 443 
Table 7); and for Gene Ontology analysis of target-gene functions, reporting the -log10 444 
binomial P-value with conservative Bonferroni correction for multiple hypothesis 445 
testing90. Correlation matrix of ChIP-seq data in Extended Data Fig.7D was produced 446 
using Morpheus software, available from Broad Institute: 447 
https://software.broadinstitute.org/morpheus/. 448 
 449 
For Fig.7B,C, GSEA was run with a geneset of the single nearest genes to super-450 
enhancers (as identified by GREAT analysis above using standard settings (GREAT 451 
v3.0.0)90, using the super-enhancers previously described in mouse PSCs2,3, versus, the 452 
ranked list of differential gene expression determined by RNA-Seq for serum/LIF 453 
control compared to CDK8/19i-adapted mouse ES PSCs. See Source Data, for SE-454 
target and expression-matched control gene lists. 455 
 456 
For Extended Data Fig.8H, GREAT analysis using standard settings (GREAT 457 
v3.0.0)90 was used to identify the set of single nearest genes (n=3,553 genes) to 458 
enhancer regions previously identified in mouse PSCs (n=10,627)2,3. Then the 459 
Log2_fold-change in RNA expression of these genes from the current study was ranked 460 
high-to-low (S/L vs 2i; S/L vs CDK8/19i), and the extent of overlap with 461 
hypergeometric test of significance, of these two ranked lists is shown as heatmap in 462 
Extended Data Fig.8H, performed by RRHO (Rank Rank Hypergeometric Overlap)85 463 
using standard settings, available at: 464 
http://systems.crump.ucla.edu/rankrank/rankranksimple.php. Colour intensity of RRHO 465 
heatmap indicates the -log10 p-value after Benjamini-Yekutieli correction of the 466 
hypergeometric overlap. 467 
 468 
 469 
STATISTICS AND DATA AVAILABILITY 470 
 471 
Statistics and reproducibility  472 
Unless otherwise specified, quantitative data are presented as Mean+/-SD and 473 
significance was assessed by the two-tailed Student’s t test; *p<0.05, **p<0.01, 474 
***p<0.001, ****p<0.0001. RRHO (Rank Rank Hypergeometric Overlap) was 475 
performed as described85 using standard settings and after Benjamini-Yekutieli 476 
correction of the hypergeometric overlap. Except when annotated otherwise, each 477 
experiment shown was carried out three times, with similar outcomes. Statistical 478 
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analyses are described in detail for each panel. No statistical methods were used to pre-479 
determine the sample size. Briefly, for differential gene expression by RNA-Seq, a 480 
threshold of FDR q-value of q<0.05, or q<0.01 was applied, as indicated in each case.  481 
In GSEA analysis, the standard threshold for significance was applied, where p<0.05 482 
and FDR q-value<0.25. Genes that were differentially expressed in the RNA-Seq were 483 
called using DESeq2 or Cufflinks 1.3.0 (details above). Immunofluorescent image 484 
analysis is described in detail above in section on embryo analysis. Statistics were 485 
performed using MACS for peak calling of the ChIP-Seq experiments. Statistical 486 
analyses of ChIP-qPCR, quantitative RT-PCR, cell culture experiments used Prism 487 
GraphPad Software (version 7.03) or Microsoft Excel. 488 
 489 
Data availability 490 
RNA-seq and ChIP-seq data are available from the GEO database under accession 491 
numbers GSE112208 and GSE127186. The mass spectrometry proteomics data are 492 
available from the ProteomeXchange Consortium/PRIDE repository with the dataset 493 
identifier PXD009200. Published datasets included in this study: Source Data 494 
Fig.4E,K. All other data supporting the findings of this study are available from the 495 
corresponding author on reasonable request. 496 
 497 
 498 
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